SUPN: Supernus Pharmaceuticals, Inc. - Summary | Jitta

Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Price
$34.82
Loss Chance
46.3%
4.61JITTA SCORE
6.77%Under Jitta Line
Jitta Ranking
72 / 1,176
1,064 / 5,159
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (42)
Recent Business Performance (43)
Financial Strength (88)
Return to Shareholders (18)
Competitive Advantage (48)
Jitta Signs
Debt LevelLow Long Term Debt
CapExVery Low
Revenue and EarningEarning decline from 2019-2022
Operating MarginDeclined
Recent Business PerformanceEarning decline 89.45% in the last quarter (yoy)
SG&A to SalesIncreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
4.61
6.77%
1.94
91.15%
1.96
201.34%
Pharmaceuticals
6.52
30.67%
3.19
90.95%
4.21
55.18%
COMPANY DESCRIPTION
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company’s commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.